首页> 外文期刊>The American Journal of Gastroenterology >Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.
【24h】

Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.

机译:肝硬化和门静脉高压症患者的管理和治疗:退伍军人事务部丙型肝炎资源中心计划和国家丙型肝炎计划的建议。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cirrhosis represents the end stage of any chronic liver disease. Hepatitis C and alcohol are currently the main causes of cirrhosis in the United States. Although initially cirrhosis is compensated, it eventually becomes decompensated, as defined by the presence of ascites, variceal hemorrhage, encephalopathy, and/or jaundice. These management recommendations are divided according to the status, compensated or decompensated, of the cirrhotic patient, with a separate section for the screening, diagnosis, and management of hepatocellular carcinoma (HCC), as this applies to patients with both compensated and decompensated cirrhosis. In the compensated patient, the main objective is to prevent variceal hemorrhage and any practice that could lead to decompensation. In the decompensated patient, acute variceal hemorrhage and spontaneous bacterial peritonitis are severe complications that require hospitalization. Hepatorenal syndrome is also a severe complication of cirrhosis but one that usually occurs in patients who are already in the hospital and, as it represents an extreme of the hemodynamic alterations that lead to ascites formation, it is placed under treatment of ascites. Recent advances in the pathophysiology of the complications of cirrhosis have allowed for a more rational management of cirrhosis and also for the stratification of patients into different risk groups that require different management. These recommendations are based on evidence in the literature, mainly from randomized clinical trials and meta-analyses of these trials. When few or no data exist from well-designed prospective trials, emphasis is given to results from large series and consensus conferences with involvement of recognized experts. A rational management of cirrhosis will result in improvements in quality of life, treatment adherence, and, ultimately, in outcomes.
机译:肝硬化代表任何慢性肝病的末期。丙型肝炎和酒精目前是美国肝硬化的主要原因。尽管最初的肝硬化可以得到补偿,但最终会变得失代偿,如存在腹水,静脉曲张破裂出血,脑病和/或黄疸所定义。这些管理建议根据肝硬化患者的补偿或失代偿状态进行划分,并有单独的部分进行肝细胞癌(HCC)的筛查,诊断和管理,因为这适用于补偿性和失代偿性肝硬化患者。在有偿患者中,主要目的是防止静脉曲张破裂出血和任何可能导致代偿失调的做法。在失代偿的患者中,急性静脉曲张破裂出血和自发性细菌性腹膜炎是严重的并发症,需要住院治疗。肝肾综合征也是肝硬化的一种严重并发症,但通常发生在已经住院的患者中,并且由于它代表导致腹水形成的血液动力学改变的极端情况,因此被置于腹水的治疗中。肝硬化并发症的病理生理学的最新进展使肝硬化的管理更加合理,也使患者分为需要不同管理的不同风险组。这些建议基于文献证据,主要来自随机临床试验和这些试验的荟萃分析。如果精心设计的前瞻性试验数据很少或根本没有,则重点放在由知名专家参与的大型系列会议和共识会议的结果上。肝硬化的合理管理将改善生活质量,治疗依从性并最终改善疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号